Jam

Hydreight Technologies reported strong Q1 2025 results, with a 34% year-over-year revenue increase to $6.53 million. GAAP revenue reached $4.54 million, and gross margin and adjusted EBITDA improved. The company achieved net profitability, ending the quarter with $6.04 million in cash. New nurse signups and pharmacy orders grew significantly. Driven by its strategic initiatives, Hydreight is focused on expansion and profitability within the digital health sector.

YANGAROO Inc. reported its eleventh consecutive quarter of positive normalized EBITDA, reaching $264,251 for Q1 2025. Despite a 7% year-over-year revenue decrease due to reduced advertising and music video deliveries, the company improved its operating income through operational efficiencies and cost control. The company is also focused on growth strategies and platform investments.

FiEE, Inc. (MINM) will resume trading on the Nasdaq on June 2, 2025, after receiving approval. The company, previously known as Minim, is refocusing on leveraging IoT, connectivity, and AI for brand management solutions, including AI-driven content creation for KOLs and brands. CEO Rafael Li highlights the re-listing as validation and emphasizes strategic initiatives for long-term growth.

Core Assets Corp. will consolidate shares at a 10:1 ratio and rebrand as Core Silver Corp., effective June 4, 2025. The trading symbol “CC” remains, while new CUSIP/ISIN designations are introduced. The company, focused on British Columbia exploration, will concentrate on its Blue Property silver project, located in a historically under-explored district it believes holds significant potential.

Fannie Mae announced the results of its tender offers for specific Connecticut Avenue Securities notes. The offers, outlined on May 22, 2025, targeted various note classes and reflect Fannie Mae’s strategy to manage risk and adjust its portfolio for market stability. Approximately $1.798 billion in principal amount of notes were tendered by the May 29, 2025 deadline. The announcement provides detailed data on the securities, including CUSIP, ISIN, and tender percentages.

Super League Enterprise (SLE) announced the successful closing of an underwritten public offering on May 30, 2025, raising approximately $550,000 in gross proceeds. The offering involved the sale of common stock at $0.12 per share, including the underwriter’s overallotment option. Funds will be used for general corporate purposes, working capital, and debt repayment, supporting Super League’s mission to revolutionize brand engagement through playable media.

VivoPower International PLC (VVPR) corrected its May 28, 2025 press release regarding its XRP digital asset strategy and a $121 million private placement. The company is shifting towards the XRP space, acquiring and managing XRP as part of a diversified digital treasury to support the XRP Ledger and DeFi infrastructure. This strategic pivot reflects a commitment to digital assets, with forward-looking statements subject to risks and uncertainties.

So-Young International (Nasdaq: SY) plans a reverse ADS split, changing its ADS ratio from 13:10 to 1:15, effective June 30, 2025. This adjustment, impacting ADS holders without required action, aims to proportionally increase the ADS price. Fractional entitlements will be sold, with net proceeds distributed to ADS holders. So-Young, connecting consumers with aesthetic treatments in China, highlights potential market risks.

Heineken embraces football fan superstition ahead of the UEFA Champions League Final. The brand is sending a self-proclaimed “jinx,” Marco Simeone, to a remote bar to watch the game, reflecting the survey that shows widespread superstitious rituals among fans. This quirky campaign highlights fan beliefs and the passionate culture around the sport.

Regeneron and Sanofi announced mixed results from their Phase 3 AERIFY trials of itepekimab for COPD. AERIFY-1 met its primary endpoint by reducing moderate or severe exacerbations in former smokers, while AERIFY-2 failed. The trials evaluated itepekimab’s impact on exacerbation frequency. Safety profiles appeared consistent across both trials. The companies are reviewing the full data.